Mitochondrial biogenesis: A therapeutic target for neurodevelopmental disorders and neurodegenerative diseases

Current Pharmaceutical Design

Volumn 20, Issue 35, 2014, Pages 5574-5593

  Uittenbogaard, Martine ^a   Chiaramello, Anne ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Adaptive mitochondrial biogenesis; Huntington s disease; Maternally inherited mitochondrial diseases; Mitochondrial DNA maintenance; Mitochondrial fusion fission; Mitophagy; Parkinson s disease; Small molecule based therapies

Indexed keywords

ARTICLE; BIOGENESIS; CELL ORGANELLE; DEGENERATIVE DISEASE; DEVELOPMENTAL DISORDER; HOMEOSTASIS; HUMAN; MITOCHONDRIAL BIOGENESIS; MITOCHONDRION; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CHILD; CHILD DEVELOPMENT; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENERGY METABOLISM; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; PROCEDURES;

REACTIVE OXYGEN METABOLITE;

ANIMALS; CHILD; CHILD DEVELOPMENT; DRUG DELIVERY SYSTEMS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; REACTIVE OXYGEN SPECIES;

EID: 84925858717     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140305224906     Document Type: Article

References (342)

1. [1] Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Annu Rev Genomics Hum Genet 2010; 11: 25-44.
2. [2] Mootha VK, Bunkenborg J, Olsen JV, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003; 115: 629-40.
3. [3] Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compedium elucidates complex I disease biology. Cell 2008; 134: 112-23.
4. [4] DiMauro S. A history of mitochondrial diseases. J Inherit Metab Dis 2011; 34: 261-76.
5. [5] De Castro IP, Martins ML, Tufi R. Mitochondrial quality control and neurological disease: an emerging connection. Expert Rev Mol Med 2010; 12: e12.
6. [6] Stetler RA, Leak R, Gao Y, Chen J. The dynamics of the mitochondrial organelle as a potential therapeutic organelle. J Cereb Blood Flow Metab 2013; 33: 22-32.
7. [7] Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001; 21: 1133-45.
8. [8] Erecinska M, Cherian S, Silver IA. Energy metabolism in mammalian brain during development. Prog Neurobiol 2004; 73: 397-445.
9. [9] Gunter TE, Gunter KK, Sheu SS, Gavin CE. Mitochondrial calcium transport: physiological and pathological relevance. Am J Physiol 1994; 267: C313-39.
10. [10] Bernstein BW, Bamburg JR. Actin-ATP hydrolysis is a major energy drain for neurons. J Neurosci 2003; 23: 1-6.
11. [11] Verstreken P, Ly CV, Venken KJ, Koh TW, Zhou Y, Bellen HJ. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 2005; 47: 365-78.
12. [12] Kann O, Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007; 292: C641-57.
13. [13] Lee CW, Peng HB. The function of mitochondria in presynaptic development at the neuromuscular junction. Mol Biol Cell 2008; 19: 150-8.
14. [14] Attwell D, Gibb A. Neuroenergetics and the kinetic design of excitatory synapses. Nat Rev Neurosci 2005; 6:841-9.
15. [15] Korf J, Gramsbergen JB. Timing of potential and metabolic brain energy. J Neurochem 2007; 103: 1697-708.
16. [16] Zhang D, Raichle ME. Disease and the brain’s dark energy. Nat Rev Neurol 2010; 6: 15-28.
17. [17] Zenisek D, Matthews G. The role of mitochondria in presynaptic calcium handling at a ribbon synapse. Neuron 2000; 25: 229-37.
18. [18] Kirichok Y, Krapivinsky G, Clapman DE. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 2004; 427: 360-4.
19. [19] Baughman JM, Perocchi F, Girgis HS, et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011; 476: 341-5.
20. [20] De Stefani D, Raffaello A, Teardo E, Szabo I, Rizzuto R. A fortykilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011; 476: 336-40.
21. [21] Rizzuto R, De Stefani D, Raffaello A, Mammucar C. Mitochondria as sensors and regulators of calcium signalling. Nature Rev 2012; 566-78.
22. [22] Chang K, Niescier RF, Min K-T. Mitochondrial matrix Ca2+ as an intrinsic signal regulating mitochondrial motility in axons. Proc Natl Acad Sci USA 2011; 108: 15456-61.
23. [23] Sheng Z-H, Cai Q. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat Rev Neurosci 2012; 13: 77-93.
24. [24] Dong Z, Saikumar P, Weinberg JM, Venkatachalan MA. Calcium in cell injury and death. Annu Rev Pathol Mech Dis 2006; 1:405-34.
25. [25] Pivovarova NB, Andrews SB. Calcium-dependent mitochondrial function and dysfunction in neurons. FEBS J 2010; 277: 3622-36.
26. [26] Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci 2005; 118: 5411-9.
27. [27] Morris RL, Hollenbeck PJ. The regulation of bidirectional mitochondrial transport is coordinated with axonal outgrowth. J Cell Sci 1993; 104: 917-27.
28. [28] Ruthel G, Hollenbeck PJ. Response of mitochondrial traffic to axon determination and differential branch growth. J Neurosci 2003; 23: 8618-24.
29. [29] Miller KE, Sheetz MP. Axonal mitochondrial transport and potential are correlated. J Cell Sci 2004; 117: 2791-804.
30. [30] Verberg J, Hollenbeck PJ. Mitochondrial membrane potential in axons increases with local nerve growth factor or semaphoring signaling. J Neurosci 2008; 28: 8306-15.
31. [31] Baxter KK, Uittenbogaard M, Yoon J, Chiaramello A. The neurogenic basic helix-loop-helix transcription factor NeuroD6 concomitantly increases mitochondrial mass and regulates cytoskeletal organization in the early stages of neuronal differentiation. ASN Neuro 2009; 1: e00016.
32. [32] Berthold CH, Fabricius C, Rydmark M, Andersen B. Axoplasmic organelles at nodes of Ranvier. I. Occurrence and distribution in large myelinated spinal root axons of the adult cat. J Neurocytol 1993; 22: 925-40.
33. [33] Mutsaers SE, Carroll WM. Focal accumulation of intra-axonal mitochondria in demyelination of the cat optic nerve. Acta Neuropathol 1998; 96: 139-43.
34. [34] Bristow EA, Griffiths PG, Andrews RM, Johnson MA, Turnbull DM. The distribution of mitochondrial activity in relation to optic nerve structure. Arch Ophtalmol 2002; 120: 791-6.
35. [35] Gross NJ, Getz GS, Rabinowitz M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. J Biol Chem 1969; 244:1552-62.
36. [36] Menzies RA, Gold PH. The turnover of mitochondria in a variety of tissues of young adult and aged rats. J Biol Chem 1971; 246: 2425-9.
37. [37] Korr H, Kurz C, Seidler TO, Sommer D, Schmitz C. Mitochondrial DNA synthesis studied autoradiographically in various cell types in vivo. Braz J Med Biol Res 1998; 31:289-98.
38. [38] Miwa S, Lawless C, von Zglinicki T. Mitochondrial turnover in liver is fast in vivo and is accelerated by dietary restriction: application of a simple dynamic model. Aging Cell 2008; 7: 920-23.
39. [39] O’Toole M, Latham R, Baqri RM, Miller KE. Modeling mitochondrial dynamics during in vivo axonal elongation. J Theor Biol 2008; 255: 369-77.
40. [40] Attardi G, Schatz G. Biogenesis of mitochondria. Annu Rev Cell Biol 1988; 4: 289-333.
41. [41] Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007; 292: C33-44.
42. [42] Schlame M, Ren M. The role of cardiolipin in the structural organization of mitochondrial membranes. Biochem Biophys Acta 2009; 1788: 2080-83.
43. [43] Amiri M, Hollenbeck JP. Mitochondrial biogenesis in the axons of vertebrate peripheral neurons. Dev Neurobiol 2008; 68: 1348-61.
44. [44] Hoppins S, Lackner L, Nunnari J. The machines that divide and fuse mitochondria. Annu Rev Biochem 2007; 76: 751-80.
45. [45] Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet 2012; 46: 265-87.
46. [46] Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science 2012; 337: 1062-5.
47. [47] Escobar-Henriques M, Anton F. Mechanistic perspective of mitochondrial fusion: Tubulation vs. fragmentation. Biochem Biophys Acta 2013; 1833: 162-75.
48. [48] Belenguer P, Pellegrini L. The dynamin GTPase OPA1: More than mitochondria. Biochem Biophys Acta 2013; 1833: 176-83.
49. [49] McBride H, Scorrano L. Mitochondrial dynamics and physiology. Biochem Byiophys Acta 2013; 1833: 148-9.
50. [50] Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fu sion and are essential for embryonic development. J Cell Biol 2003; 160: 189-200.
51. [51] Chen H, McCaffery M, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2007; 130: 548-62.
52. [52] Delettre C, Lenaers G, Griffoin JM, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26: 207-10.
53. [53] Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26: 211-15.
54. [54] Züchner S, Mersiyanova LV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-51.
55. [55] Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science 2005; 307: 1282-8.
56. [56] Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci 2007; 27: 422-30.
57. [57] Elgass K, Pakay J, Ryan MT, Palmer CS. Recent advances into the understanding of mitochondrial fission. Biochem Biophys Acta 2013; 1833: 150-61.
58. [58] Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004; 119: 873-87.
59. [59] Verstreken P, Ly CV, Venken KJ, Koh TW, Zhou Y, Bellen HJ. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron 2005; 4: 365-78.
60. [60] Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nature Rev Neurosci 2008; 9: 505-18.
61. [61] Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009; 18: 169-76.
62. [62] Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 2010; 67: 3435-47.
63. [63] Narendra DP, Youle RJ. Neurodegeneration: Trouble in the cell’s powerhouse. Nature 2012; 483: 418-9.
64. [64] Rugarli EI, Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J 2012; 31: 1336-49.
65. [65] Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Diff 2013; 20: 31-42.
66. [66] Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011; 12: 9-14.
67. [67] Holtzman E, Novikoff AB. Lysosomes in the rate sciatic nerve following crush. J Cell Biol 1965; 27: 651-69.
68. [68] Cai Q, Zakaria HM, Simone A, Sheng ZH. Spatial Parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons. Curr Biol 2012; 22: 545-52.
69. [69] Maday S, Wallace KE, Holzbaur EL. Autophagosomes initiate distally and mature during transport toward the cell soma in primary neurons. J Cell Biol 2012; 196: 407-11.
70. [70] Maday S, Holzbaur EL. Autophagosome assembly and cargo capture in the distal axon. Autophagy 2012; 8: 858-60.
71. [71] Jin SM, Youle RJ. PINK1-and Parkin-mediated mitophagy at a glance. J Cell Sci 2012; 125: 795-9.
72. [72] Wang X, Winter D, Ashrafi G, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011;147: 893-906.
73. [73] Kane LA, Youle RJ. PINK1 and Parkin flag Miro to direct mitochondrial traffic. Cell 2011:147, 721-3.
74. [74] Gegg ME, Cooper JM, Chau KY, Schapira AH, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PIK1/parkindependent manner upon induction of mitophagy. Hum Mol Genet 2010; 19: 4861-70.
75. [75] Glauser L, Sonnay S, Stafa K, Moore DJ. Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. J Neurochem 2011; 118: 636-45.
76. [76] Sarraf SA, Raman M, Guarani-Pereira V, et al. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 2013; 496: 372-6.
77. [77] Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-8.
78. [78] Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary earlyonset Parkinson’s disease caused by mutations in PINK1. Science 2004; 304: 1158-60.
79. [79] Rubinsztein DC, DiFiglia M, Hintz N, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 2005; 1: 11-22.
80. [80] Ventruti A, Cuervo AM. Autophagy and neurodegeneration. Curr Neurol Neurosci Rep 2007; 7: 443-51.
81. [81] Schapira AHV. Mitochondrial pathology in Parkinson’s disease. Mount Sin J Med 2011; 78: 872-81.
82. [82] Battevi Y, La Spada AR. Mitochondrial autophagy in neural function, neurodegenerative disease, neural cell death, and aging. Neurobiol Dis 2011; 43: 46-51.
83. [83] Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 2008; 88: 611-38.
84. [84] Onyango IG, Lu J, Rodova M, Lezi E, Crafter AB, Swerdlow RH. Regulation of neuronal mitochondrial biogenesis and relevance to brain health. Biochem Biophys Acta 2010; 1802: 228-34.
85. [85] Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 2007; 8: 870-9.
86. [86] Wallace DC. The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement. Gene 2005; 354: 169-80.
87. [87] Kaneda H, Hayashi J, Takahama S, Taya C, Lindahl KF, Yonekawa H. Elimination of paternal mitochondrial DNA in intraspecific crosses during early mouse embryogenesis. Proc Natl Acad Sci USA 1995; 92: 4542-6.
88. [88] Shoubridge EA. Mitochondrial DNA segregation in the developing embryo. Hum Reprod 2000; 15: 229-34.
89. [89] Chen XJ, Butow RA. The organization and inheritance of the mitochondrial genome. Nat Rev Genet 2005; 6: 815-25.
90. [90] Spelbrink JN. Functional organization of mammalian mitochondrial DNA in nucleoids: history, recent developments, and future challenges. IUBMB Life 2010; 62: 19-32.
91. [91] Bogenhagen DF. Mitochondrial DNA nucleoid structure. Biochem Biophys Acta 2012; 1819: 914-20.
92. [92] Iborra F, Kimura H, Cook P. The functional organization of mitochondrial genomes in human cells. BMC Biol 2004; 2: 9.
93. [93] Wang Y, Bogenhagen DF. Human mitochondrial DNA nucleoids are linked to protein folding machinery and metabolic enzymes at the mitochondrial inner membrane. J Bio Chem 2006; 281: 25791-802.
94. [94] Gilkerson RW, Schon EA, Hernandez E, Davidson MM. Mitochondrial nucleoids maintain genetic autonomy but allow for functional complementation. J Cell Biol 2008; 181: 1117-28.
95. [95] Garrido N, Griparic L, Jokitalo E, Wartiovaara J, van der Bliek AM, Spelbrink JN. Composition and dynamics of human mitochondrial nucleoids. Mol Biol Cell 2003; 14: 1583-96.
96. [96] Bogenhagen DF, Rousseau D, Burke S. The layered structure of human mitochondrial DNA nucleoids. J Biol Chem 2008; 283: 3665-75.
97. [97] Ylikallio E, Tyynismaa H, Tsutsui H, Ide T, Suomalainen A. High mitochondrial DNA copy number has detrimental effects in mice. Hum Mol Genet 2010; 19: 2695-705.
98. [98] Gilkerson RW. Mitochondrial DNA nucleoids determine mitochondrial genetics and dysfunction. Int J Biochem Cell Biol 2009; 41: 1899-906.
99. [99] Jacobs HT, Lehtinen SK, Spelbrink JN. No sex please, we’re mitochondria: a hypothesis on the somatic unit of inheritance of mammalian mtDNA. Bioessays 2000; 22: 564-72.
100. [100] Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 2004; 18: 357-68.
101. [101] Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-39.
102. [102] Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): Transcriptonal coactivator and metabolic regulator. Endocrine Rev 2003; 24: 78-90.
103. [103] Estesbauer H, Oberkofler H, Krempler F, Patsch W. Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chro mosomal localization, and tissue expression. Genomics 1999; 62: 98-102.
104. [104] Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem 2002; 277: 1645-8.
105. [105] Cowell R, Blake KR, Russel JW. Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain. J Comp Neurol 2007; 502: 1-18.
106. [106] Lin J, Wu PH, Tarr PT, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 2004; 119: 121-35.
107. [107] Scarpulla RC. Transcriptional activators and coactivators in the nuclear control of mitochondrial function in mammalian cells. Gene 2002; 286: 81-9.
108. [108] Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999; 98: 115-24.
109. [109] Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000; 106: 847-56.
110. [110] Rasbach KA, Schnellmann RG. PGC-1alpha over-expression promotes recovery from mitochondrial dysfunction and cell injury. Biochem Biophys Res Comm 2007; 355: 734-9.
111. [111] Geissler A, Krimmer T, Bömer U, Guiard B, Rassow J, Pfanner N. x Membrane potential-driven protein import into mitochondria. Mol Biol Cell 2007; 11: 3977-91.
112. [112] Wiedermann N, Frazier AE, Pfanner N. The protein import machinery of mitochondria. J Biol Chem 2004; 279: 14473-6.
113. [113] Neupert W, Herrmann JH. Translocation of proteins into mitochondria. Annu Rev Biochem 2007; 76: 723-49.
114. [114] Tsunemi T, La Spada AR. PGC-1α at the intersection of bioenergetics regulation and neuronal function: From Huntington’s disease to Parkinson’s disease and beyond. Prog Neurobiol 2012; 97: 142-51.
115. [115] Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem 2006; 97: 673-83.
116. [116] Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochem Biophys Acta 2011; 1813: 1269-78.
117. [117] Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 2012; 23: 459-66.
118. [118] Huo L, Scarpulla RC. Mitochondrial DNA instability and periimplantation lethality associated with targeted disruption of nuclear respiratory factor 1 in mice. Mol Cell Biol 2001; 21: 644-54.
119. [119] Ristevski S, O’Leary DA, Thornell AP, Owen MJ, Kola I, Hertzog PJ. The ETS transcription factor GABPα is essential for early embryogenesis. Mol Cell Biol 2004; 24: 5844-9.
120. [120] Wong-Riley MT. Bigenomic regulation of cytochrome c oxidase in neurons and the tight coupling between neuronal activity and energy metabolism. Adv Exp Med Biol 2012; 748: 283-304.
121. [121] Wong-Riley MT. Cytcohrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci 1989; 12: 94-101.
122. [122] Ongwijitwat S, Wong-Riley MT. Is nuclear respiratory factor 2 a master transcriptional coordinator for all ten nuclear-encoded cytochrome c oxidase subunits in neurons? Gene 2005; 360: 65-77.
123. [123] Ongwijitwat S, Liang HL, Graboyes EM, Wong-Riley MT. Nuclear respiratory factor 2 senses changing cellular energy demands and its silencing down-regulates cytochrome oxidase and other target gene mRNAs. Gene 2006; 374: 39-49.
124. [124] Yang SJ, Liang HL, Wong-Riley MT. Activity-dependent transcriptional regulation of nuclear respiratory factor-1 in cultured rat visual cortical neurons. Neuroscience 2006; 141: 1181-92.
125. [125] Dhar SS, Ongwijitwat S, Wong-Riley MT. Nuclear respiratory factor 1 regulates all ten nuclear-encoded subunits of cytochrome c oxidase in neurons. J Biol Chem 2008; 283: 3120-9.
126. [126] Dhar SS, Wong-Riley MT. Coupling of energy metabolism and synaptic transmission at the transcriptional level: role of nuclear respiratory factor 1 I regulating both cytochrome c oxidase and NMDA glutamate receptor subunit genes. J Neurosci 2009; 29: 483-92.
127. [127] Larsson NG, Wang JM, Wilhelmsson H, et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nature Genet 1998; 18: 231-6.
128. [128] Hance N, Ekstrand MI, Trifunovic A. Mitochondrial DNA polymerase gamma is essential for mammalian embryogenesis. Hum Mol Genet 2005; 14: 1775-83.
129. [129] Falkenberg M, Larsson NG, Gustafsson CM. DNA replication and transcription in mammalian mitochondria. Annu Rev Biochem 2007; 76: 679-99.
130. [130] Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, Gustafsson CM. Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat Genet 2002; 31: 289-94.
131. [131] Gaspari M, Falkenberg M, Larsson NG, Gustafsson CM. The mitochondrial RNA polymerase contributes critically to promoter specificity in mammalian cells. EMBO J 2004; 23: 4606-14.
132. [132] Alam TI, Kanki T, Muta T, et al. Human mitochondrial DNA is packaged with TFAM. Nucleic Acids Res 2003; 31: 1640-5.
133. [133] Kaufman BA, Durisic N, Mativetsky JM, et al. The mitochondrial transcription factor TFAM coordinates the assembly of multiple DNA molecules into nucleoid-like structures. Mol Biol Cell 2007; 18: 3225-36.
134. [134] Ekstrand M, Falkenberg M, Rantanen A, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet 2004; 13: 935-44.
135. [135] Pohjoismaki JL, Wanrooij S, Hyvarinen AK, et al. Alterations to the expression level of mitochondrial transcription factor A, TFAM, modify the mode of mitochondrial DNA replication in cultured human cells. Nucleic Acids Res 2006; 34: 5815-28.
136. [136] Kang D, Kim SH, Hamasaki N. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion 2007; 7:39-44.
137. [137] Sörensen L, Ekstrand M, Silva JP, et al. Late-onset corticohippocampal neurodepletion attributable to catastrophic failure of oxidative phosphorylation in MILON mice. J Neurosci 2001; 21: 8082-90.
138. [138] Ekstrand M, Terzioglu M, Galter D, et al. Progressive parkinsonism in mice with respiration-chain-deficient dopamine neurons. Proc Natl Acad Sci USA 2007; 104: 1325-30.
139. [139] Galter D, Pernold K, Yoshitake T, et al. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson’s disease. Genes Brain Behav 2010; 9: 173-81.
140. [140] Milenkovic D, Matic S, Kühl I, et al. Twinkle is an essential mitochondrial helicase required for synthesis of nascent D-loop strands and complete mtDNA replication. Hum Mol Genet 2013; doi:10.1093/hmg/ddt051.
141. [141] Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001; 28: 223-31.
142. [142] Korhonen JA, Gaspari M, Falkenberg M. TWINKLE has 5’->3’ DNA helicase activity and is specifically stimulated by mitochondrial single-stranded DNA-binding protein. J Biol Chem 2003; 278: 48627-32.
143. [143] Korhonen JA, Pham XH, Pellegrini M, Falkenberg M. Reconstitution of a minimal mtDNA replisome in vitro. EMBO J 2004; 23: 2423-29.
144. [144] Tyynismaa H, Sembongi H, Bokori-Brown M, et al. Twinkle helicase is essential for mtDAN maintenance and regulates mtDNA copy number. Hum Mol Genet 2004; 13: 3219-27.
145. [145] Suomalainen A, Majander A, Wallin M, et al. Autosomal dominant progressive external ophtalmoplegia with multiple deletions of mtDNA: clinical, biochemical, and molecular genetic features of the 10q-linked disease. Neurology 1997; 48: 1244-53.
146. [146] Tyynismaa H, Mjosund KP, Wanrooij S, et al. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a lateonset mitochondrial disease in mice. Proc Natl Acad Sci USA 2005; 102: 17687-92.
147. [147] Wanrooij S, Falkenberg M. The human mitochondrial replication fork in health and disease. Biochem Biophys Acta 2010; 1797: 1378-88.
148. [148] Copeland WC. Defects in mitochondrial DNA replication and human disease. Crit Rev Biochem Mol Biol 2012; 47: 64-74.
149. [149] Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-85.
150. [150] Fogarty S, Hawley SA, Green KA, Saner N, Mustard KJ, Hardie DG. Calmodulin-dependent protein kinase-β activates AMPK without forming a stable complex: synergistic effects of Ca2+ and AMP. Biochem J 2010; 426: 109-18.
151. [151] Bierbaum M. Activating AMP-activated protein kinase without AMP. Mol Cell 2005; 19: 289-90.
152. [152] Viollet B, Horman S, Leclerc J, et al. AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 2010; 45: 276-95.
153. [153] Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev 2009; 89: 1025-78.
154. [154] Cantó C, Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci 2010; 67: 3407-23.
155. [155] Barnes AP, Lilley BN, Pan YA, et al. LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007; 129: 549-63.
156. [156] Anderson KA, Ribar TJ, Lin F, et al. Hypothalamic CAMKK2 contributes to the regulation of energy balance. Cell Metab 2008; 7: 377-88.
157. [157] Green MF, Anderson KA, Means AR. Characterization of the CaMKKβ-AMPK signaling complex. Cell Signal 2011; 23: 2005-12.
158. [158] Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 2002; 25: 15983-7.
159. [159] Bergeron R, Ren JM, Cadman KS, et al. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 2001; 281: E1340-6.
160. [160] Reznick RM, Shulman GI. The role of AMP-activated protein kinase in mitochondrial biogenesis. J Physiol 2006; 574:33-39.
161. [161] Jäger S, Handschin C, St-Pierre J, Spiegelman BM. AMP-actiavted protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007; 104: 12017-22.
162. [162] Yu L, Yang SJ. AMP-activated protein kinase mediates activitydependent regulation of peroxisome proliferator-activated receptor γ coactivator-1α and nuclear respiratory factor 1 expression in rat visual cortical neurons. Neuroscience 2010; 169: 23-38.
163. [163] Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M. AMP-activated protein kinase: a potential player in Alzheimer’s disease. J Neurochem 2011; 118: 460-74.
164. [164] Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D. AMPactivated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J 2011; 434: 503-12.
165. [165] Vingtdeux V, Davies P, Dickson DW, Marambaud P. AMPK is abnormally activated in tangle-and pre-tangle-bearing neurons in Alzheimer’s disease and other tauopathies. Acta Neuropathol 2011; 121: 337-49.
166. [166] Yoon SO, Park DJ, Ryu JC, et al. JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron 2012; 75: 824-37.
167. [167] Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010; 285:9100-9113.
168. [168] Vingtdeux V, Chadakkar P, Zhao H, d’Abramo C, Davies P, Marambaud P. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J 2011; 25: 219-31.
169. [169] Choi JS, Park C, Jeong JW. AMP-activated proteine kinase is activated in Parkinson’s disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun 2010; 391: 147-51.
170. [170] Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
171. [171] Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 2003; 39: 889-909.
172. [172] Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol 1989; 26: 719-23.
173. [173] Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989; 8649: 1269.
174. [174] Parker WD Jr, Parks JK, Swerdlow RH. Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 2008; 1189: 215-18.
175. [175] Liang CL, Wang TT, Luby-Phelps K, German DC. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson’s disease. Exp Neurol 2007; 203: 370-80.
176. [176] Cantó C, Auwerx J. PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20: 98-105.
177. [177] Dali-Youcef N, Lagouge M, Froelich S, Koehl C, Schoojans K, Auwerx J. Sirtuins: the “magnificent seven”, function, metabolism and longevity. Ann Med 2007; 39: 335-45.
178. [178] Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13.
179. [179] Cohen DE, Supinski AM, Bonkowski MS, Domnez G, Guarente LP. Neuronal SIRT1 regulates endocrine and behavioral responses to calorie restriction. Genes Dev 2009; 23: 2812-7.
180. [180] Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003; 100: 10794-9.
181. [181] Hisahara S, Chiba S, Matsumoto H, et al. Histone deacetylase SIRT1 modulates neuronal differentiation by its nuclear translocation. Proc Natl Acad Sci USA 2008; 105: 15599-604.
182. [182] Gao J, Wang WY, Mao YW, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010; 466: 1105-9.
183. [183] Michán S, Li Y, Chou MM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci 2010; 30: 9695-07.
184. [184] Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRt1 activation prevent axonal degeneration. Science 2004; 305: 1010-3.
185. [185] Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NFkappaB signaling. J Biol Chem 2005; 280: 40364-74.
186. [186] Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic sclerosis. EMBO J 2007; 26: 3169-79.
187. [187] Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010; 142: 320-32.
188. [188] Rodgers JT, Lerin C, Haas W, Gysi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-8.
189. [189] Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007; 26: 1913-23.
190. [190] Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458: 1056-60.
191. [191] Sasaki T, Maier B, Koclega KD, et al. Phosphorylation regulates SIRT1 function. PLoS One 2008; 3: e4020.
192. [192] Kang H, Jung JW, Kim MK, Chung JH. CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA damage. PLoS One 200; 4: e6611.
193. [193] Nasrin N, Kaushik VK, Fortier E, et al. JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 2009; 4: e8414.
194. [194] Guo X, Williams JG, Schug TT, Li X. DYRRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem 2010; 285: 13223-32.
195. [195] Guo X, Kesimer M, Tolun G, et al. The NAD+-dependent protein deacetylase activity of SIRT1 is regulated by its oligomeric status. Sci Rep 2012; 2: 640.
196. [196] Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J Biol Chem 2005; 280: 16456-60.
197. [197] Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1_ and SIRT1 pathways. FEBS Lett 2008; 582: 46-53.
198. [198] Fulco M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPKmediated regulation of Nampt. Dev Cell 2008; 14: 661-73.
199. [199] Costford SR, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. Am. J. Physiol. Endocrinol Metab 2010; 298: E117-26.
200. [200] Cantó C, Jiang LQ, Deshmukh AS, et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 2010; 11: 213-9.
201. [201] Van Blerkom J, Davies P, Mathwig V, Alexander S. Domains of high-polarized and low-polarized mitochondria may occur in mouse and human oocytes and early embryos. Human Rep 2002; 17: 393-406.
202. [202] Cree LM, Samuels DC, de Sousa Lopes SC, et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet 2008; 40: 249-54.
203. [203] Cordeau-Lossouam L, Vayssière JL, Larcher JC, Gros F, Croizat B. Mitochondrial maturation during neuronal differentiation in vivo and in vitro. Biol Cell 1991;1: 57-65.
204. [204] Vayssière JL, Cordeau-Lossouam L, Larcher JC, Baseville M, Gros F, Croizat B. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In vitro Cell Dev Biol 1992, 28A: 763-72.
205. [205] Schwab MH, Druffel-Augustin S, Gass P, et al. Neuronal basic helix-loop-helix proteins (NEX, NeuroD, NDRF): spatiotemporal expression and targeted disruption of the Nex gene in transgenic mice. J Neurosci 1998; 18: 1408-18.
206. [206] Schwab MH, Bartholomae A, Heimrich B, et al. Neuronal basic helix-loophelix proteins (NEX and BETA/NeuroD) regulate terminal granule cell differentiation in the hippocampus. J Neurosci 2000; 20: 3714-24.
207. [207] Wu SX, Goebbels S, Nakamura K, et al. Pyramidal neurons of upper cortical layers generated by NEX-positive progenitor cells in the subventricular zone. Proc Natl Acad Sci USA 2005; 102: 17172-7.
208. [208] Uittenbogaard M, Chiaramello A. Constitutive overexpression of the basic helix-loop-helix Nex/MATH-2 transcription factor promotes neuronal differentiation of PC12 cells and neurite regeneration. J Neurosci Res 2002; 67: 235-45.
209. [209] Uittenbogaard M, Chiaramello A. Expression profiling upon Nex1/MATH-2-mediated neuritogenesis in PC12 cells and its implication in regeneration. J Neurochem 2004; 91: 1332-43.
210. [210] Uittenbogaard M, Baxter KK, Chiaramello A. NeuroD6 genomic signature bridging neuronal differentiation to survival via the molecular chaperone network. J Neurosci 2010a; 88: 33-54.
211. [211] Baxter KK, Uittenbogaard M, Chiaramello A. The neurogenic basic helix-loop-helix transcription factor NeuroD6 enhances mitochondrial biogenesis and bioenergetics to confer tolerance of neuronal PC12-NeuroD6 cells to the mitochondrial stressor rotenone. Exp Cell Res 2012; 318: 2200-14.
212. [212] Dotti CG, Sullivan CA, Banker GA. The establishment of polarity by hippocampal neurons in culture. J Neurosci 1988; 8: 1454-68.
213. [213] Uittenbogaard M, Baxter KK, Chiaramello A. The neurogenic basic helix-loop-helix transcription factor NeuroD6 confers tolerance to oxidative stress by triggering an antioxidant response and sustaining the mitochondrial biomass. ASN Neuro 2010b; 2: e00034.
214. [214] Voccoli V, Colombaioni L. Mitochondrial remodeling in differentiating neuroblasts. Brain Res 2009; 152: 15-29.
215. [215] Facucho-Oliveira JM, St John JC. The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. Stem Cell Rev Rep 2009; 5: 140-58.
216. [216] Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation or self-renewal of ES cells. Nat Genet 2000; 24: 372-6.
217. [217] Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 2003; 113: 643-55.
218. [218] St John JC, Ramalho-Santos J, Gray HL, et al. The expression of mitochondrial DNA transcription factors during early cardiomyocyte in vitro differentiation from human embryonic stem cells. Cloning Stem Cells 2005; 7: 141-53.
219. [219] Facucho-Oliveira JM, Alderson J, Spikings EC, Egginton S, St John JC. Mitochondrial DNA replication during differentiation of murine embryonic stem cells. J Cell Sci 2007; 120: 4025-34.
220. [220] Li J, Pan G, Cui K, Liu Y, Xu S, Pei D. A dominant-negative form of mouse SOX2 induces trophectoderm differentiation and progressive polyploidy in mouse embryonic stem cells. J Biol Chem 2007; 282: 19481-92.
221. [221] Chung S, Dzeja PP, Faustino RS, Perrez-Terzic C, Behfar A, Terzic A. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiov Med 2007; 4: S60-7.
222. [222] Kondoh H, Lleonart ME, Nakashima Y, et al. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal 2007; 9: 293-9.
223. [223] Parket GC, Acsadi G, Brenner CA. Mitochondria: Determinants of stem cell fate? Stem Cells Dev 2009; 18: 803-6.
224. [224] Bain G, Ray WJ, Yao M, Gottlieb DI. Retinoic acid promotes neural and represses mesodermal gene expression in mouse embryonic stem cells in culture. Biochem Biophys Res Comm 1996; 223: 691-4.
225. [225] Gajovic S, St-Onge L, Yokota Y, Gruss P. Retinoic acid mediates Pax6 expression during in vitro differentiation of embryonic stem cells. Differentiation 1997; 62: 187-92.
226. [226] Bibel M, Richter J, Schrenk K, et al. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat Neurosci 2004; 7: 1003-9.
227. [227] Nordin N, Li M, Mason JO. Expression profiles of Wnt genes during neural differentiation of mouse embryonic stem cells. Cloning Stem Cells 2008; 10: 37-48.
228. [228] Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol Mech Dis 2010; 5: 297-348.
229. [229] Duchen MR, Szabadkai G. Roles of mitochondria in human disease. Essays Biochem 2010; 47: 115-37.
230. [230] Smith RAJ, Hartley RC, Cochemé Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci 2012; 33: 341-52.
231. [231] Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988a; 242: 1427-30.
232. [232] Wallace DC, Zheng X, Lott MT, et al. Familial mitochondrial encephalopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988b; 55: 601-10.
233. [233] Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283: 1482-8.
234. [234] Wallace DC, Brown MD, Lott MT. Mitochondrial DNA variation in human evolution and disease. Gene 1999; 238: 211-30.
235. [235] Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428-33.
236. [236] Wallace DC. Mitochondrial DNA sequence variation inhuman evolution and disease. Proc Natl Acad Sci USA 1994; 91: 8739-46.
237. [237] Man PY, Tunrbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet 2002; 39: 162-9.
238. [238] Sciacco M, Bonilla E, Schon EA, DiMauro S, Moraes CT. Distribution of wild type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 1994; 3: 13-9.
239. [239] Larsson NG, Clayton DA. Molecular genetic aspects of human mitochondrial disorders. Annu Rev Genet 1995; 29: 151-78.
240. [240] Wenz T, Willaims SL, Bacman SR, Moraes CT. Emerging therapeutic approaches to mitochondrial diseases. Dev Dis Res Rev 2010; 16: 219-29.
241. [241] Schon EA, Przedborski. Mitochondria: the next (neurode) generation. Neuron 2011; 70: 1033-53.
242. [242] DiMauro S, Schon EA. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008; 31: 91-123.
243. [243] Schapira AH. Mitochondrial disease. Lancet 2006; 368: 70-82.
244. [244] Finsterer J. Inherited mitochondrial neuropathies. J Neurol Sci 2011; 304: 9-16.
245. [245] Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalopathies. Nature 1990; 348: 651-3.
246. [246] Kobayashi Y, Momoi MY, Tominaga K, et al. A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes). Biochem Biophys Res Commun 1990; 173: 816-22.
247. [247] Schon EA, Koga Y, Davidson M, Moraes CT, King MP. The mitochondrial tRNA(Leu)(UUR) mutation in MELAS: a model for pathogenesis. Biochem Biophys Acta 1992; 1101: 206-9.
248. [248] Kobayashi Y, Momoi MY, Tominaga K, et al. Respirationdeficient cells are caused by a single point mutation in the mitochondrial tRNLeu (UUR) gene in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Am J Hum Genet 1991; 49: 590-9.
249. [249] Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): current concepts. J Child Neurol 1994; 9: 4-13.
250. [250] Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes: basic concepts, clinical phenol type, and therapeutic management of MELAS syndrome. Ann NY Acad Sci 2008; 1142: 133-58.
251. [251] Turnbull HE, Lax NZ, Diodato D, Ansorge O, Turnbull DM. The mitochondrial brain: From mitochondrial genome to neurodegeneration. Biochem Byophys Acta 2010; 1802: 111-21.
252. [252] Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragger-red fiber disease (MERRF) is associate with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61:931-7.
253. [253] Naumann M, Kiefer R, Toyka KV, Sommer C, Seibel P, Reichmann H. Mitochondrial dysfunction with myoclonus epilepsy and ragged-red fibers point mutation in nerve, muscle, and adipose tissue of a patient with multiple symmetric lipomatosis. Muscle Nerve 1997; 20: 833-9.
254. [254] Tanji K, Kunimatsu T, Vu TH, Bonilla E. Neuropathological features of mitochondrial disorders. Semin Cell Dev Biol 2001; 12: 429-39.
255. [255] Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 1997; 120: 1713-21.
256. [256] DiMauro S, Hirano M, Kaufman P, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol 2002; 89: 217-29.
257. [257] Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005; 3: e101.
258. [258] Ma D, Li S, Lucas EK, Cowell RM, Lin JD. Neuronal inactivation of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) protects mice from diet-induced obesity and leads to degenerative lesions. J Biol Chem 2010; 285: 39087-95.
259. [259] Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Annu Neurol 1997; 41: 646-53.
260. [260] Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapir AH. Mitochondrial defect in Huntington’s disease caudate nucleus. Annu Neurol 1996; 39: 385-9.
261. [261] Seong IS, Ivanova E, Lee JM, et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005; 14: 2871-80.
262. [262] Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression by PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
263. [263] Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab 2006; 4: 349-62.
264. [264] Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC-1alpha function in muscle in Huntington’s disease. Hum Mol Genet 2009; 18: 3048-65.
265. [265] Weydt P, Soyal SM, Gellera C, et al. The gene coding for PGC-1alpha modifies age at onset in Huntington’s disease. Mol Neurodegener 2009; 4, 3.
266. [266] Xiang Z, Valenza M, Cui L, et al. Peroxisome-proliferatoractivated receptor gamma coactivator 1 {alpha} contributes to dysmyelination in experimental models of Huntington’s disease. J Neurosci 2011; 31: 9544-53.
267. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2010; 2, 52-73.
268. [268] Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 2011; 144: 689-702.
269. [269] Looman C, Abrink M, Mark C, Hellman L. KRAB zinc finger proteins: an analysis of the molecular mechanisms governing their increase in numbers and complexity during evolution. Mol Biol Evol 2002; 19: 2118-30.
270. [270] Zhu X, Perry G, Moreira PL, et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 2006; 9: 147-53.
271. [271] Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 2001; 21: 3017-23.
272. [272] Wang X, Su B, Siedlack SL, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 2008; 105: 19318-23.
273. [273] Qin W, Haroutunian V, Katsel P, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009; 66: 352-61.
274. [274] Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem 2011; 120: 419-29.
275. [275] Herzig S, Long F, Jhala US, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001; 413: 179-83.
276. [276] Yamamoto-Sasaki M, Ozawa H, Saito T, Rosler M, Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 1999; 824: 300-3.
277. [277] Suomalainen A. Therapy for mitochondrial disorders: Little proof, high research activity, some promise. Sem Fetal Neonatal Med 2011; 16: 236-40.
278. [278] Moraes CT. Making the most of what you’ve got: optimizing residual OXPHOS function in mitochondrial diseases. EMBO Mol Med 2009; 1: 357-9.
279. [279] Srivastava S, Barrett JN, Moraes CT. PGC-1α/β upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations. Hum Mol Genet 2007; 16: 993-1005.
280. [280] Srivastava S, Diaz F, Iommarini L, Aure K, Lombes A, Moraes CT. PGC-1α/β induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum Mol Genet 2009; 18: 1805-12.
281. [281] Wenz T, Diaz F, Hernandez D, Moraes CT. Endurance exercise is protective for mice with mitochondrial myopathy. J Appl Physiol 2009; 106: 1712-9.
282. [282] Taivassalo T, Haller RG. Implications of exercise training in mtDNA defects-use it or lose it? Biochem Biophys Acta 2004; 1659: 221-31.
283. [283] Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005; 37: 2094-101.
284. [284] Torraco A, Diaz F, Vempati UD, Moraes CT. Mouse models of oxidative phosphorylation defects: Powerful tools to study the pathobiology of mitochondrial diseases. Biochem Biophys Acta 2009; 1793: 171-80.
285. [285] Tyynismaa H, Suomalainen A. Mouse models of mitochondrial DNA defects and their relevance for human disease. EMBO Reports 2009; 10: 137-43.
286. [286] Diaz F, Thomas CK, Garcia S, Hernandez D, Moraes CT. Mice lacking COX10 in skeletal muscle recapitulate the phenotype of progressive mitochondrial myopathies associated with cytochrome c oxidase deficiency. Hum Mol Genet 2005; 14: 2737-48.
287. [287] DiMauro S, Mendell JR, Sahenk Z, et al. Fatal infantile mitochondrial myopathy and renal dysfunction due to cytochrome c oxidase deficiency. Neurology 1980; 30: 795-804.
288. [288] Minchom, PE, Dormer RL, Hughes IA, et al. Fatal infantile mitochondrial myopathy due to cytochrome c oxidase deficiency. J. Neurol. Sci. 1983; 60: 453-63.
289. [289] Barros MH, Carlson CG, Glerum DM, Tzagoloff A. Involvement of mitochondrial ferredoxin and Cox15p in hydroxylation of heme O. FEBS Lett 2001; 492: 133-38.
290. [290] Antonicka H, Mattman A, Carlson CG, et al. Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. Am J Hum Genet 2003; 72: 101-14.
291. [291] Khalimonchuck O, Rödel G. Biogenesis of cytochrome c oxidase. Mitochondrion 2005; 5: 363-88.
292. [292] Viscomi C, Bottani E, Civiletto G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α. Cell Metab 2011; 14: 80-90.
293. [293] Dell’Agnello C, Leo S, Agostino A, et al. Increased longevity and refractoriness to Ca(2+)-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet 2007; 16: 4310-444.
294. [294] Wenz T. PGC-1α activation as a therapeutic approach in mitochondrial disease. IUBMB Life 2009; 6: 1051-62.
295. [295] Nunnari J, Suomalainen A. Mitochondria: In sickness and in health. Cell 2012; 148: 1145-59.
296. [296] Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol 2005; 4: 14.
297. [297] Lehrke M, Lazar M. The many faces of PPARgamma. Cell 2005; 123: 993-9.
298. [298] Semple R, Chatterjee V, O’Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest Ophtalmol Vis Sci 2006; 16: 581-9.
299. [299] Risner M, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 2006; 6: 246-54.
300. [300] Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008; 8: 249-56.
301. [301] Yatsuga S. Suomalainen A. Effect of bezafibrate treatment on lateonset mitochondrial myopathy in mice. Hum Mol Genet 2012; 21: 526-35.
302. [302] Johri A, Calingasan NY, Hennessey TM, et al. Pharmacological activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet 2012; 21: 1124-37.
303. [303] Bastin J, Aubey F, Rötig A, Munnich A, Djouadi F. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients’ cells lacking its components. J Clin Endocrinol Metab 2008; 93: 1433-41.
304. [304] Wenz T, Wang X, Marini M, Moraes CT. A metabolic shift induced by a PPAR panagonist markedly reduces the effects of pathogenic mitochondrial tRNA mutations. J Cell Mol Med 2011; 15: 2317-25.
305. [305] Corton JM, Gillepsie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activating protein kinase in intact cell? Eur J Biochem 1995; 229: 558-65.
306. [306] Merrill, GF. Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997; 273: 1107-12.
307. [307] Golubitzky A, Dan P, Weissman S, Link G, Wikstrom JD, Saada A. Screening for active small molecules in mitochondrial complex I deficient patient’s fibroblasts, reveal AICAR as the most beneficial compound. PLoS One 2011. 6:e26883.
308. [308] Zhou G, Myers R, Li Y, et al. Role of AMK-activated protein kinase in mechanism of metfomin action. J Clin Invest 2001; 108: 1167-74.
309. [309] Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348: 607-14.
310. [310] Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: A common mechanism contributing to their antidiabetic actions? Diabetes 2004; 53: 1052-9.
311. [311] Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011; 286: 1-11.
312. [312] Lee SS, Lee RY, Fraser AG, Kamath RS, Ahringer J, Ruvkun G. A systematic RNAi screen identifies a critical role for mitochondria in C. ELEGANS. NAT Genet 2003; 33: 40-8.
313. [313] Copeland JM, Cho J, Lo T Jr, et al. Extension of Drosophila life span by RNAi of the mitochondrial respiratory chain. Curr Biol 2009; 19: 1591-8.
314. [314] Vafai SB, Mootha VK. Mitochondrial disorders as windows into an ancient organelle. Nature 2012; 491: 374-83.
315. [315] Houtkooper RH, Auwerx J. Exploring the therapeutic space around NAD+. J Cell Biol 2012; 199: 205-9.
316. [316] Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Annu. N.Y. Acad. Sci 2009; Suppl 1, E10-19.
317. [317] Domnez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 2013; 5: 344-52.
318. [318] Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 2003; 100: 2911-6.
319. [319] Cohen DE, Cui L, Supinski A, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of TORC1 and CREB transcriptional pathway. Nat Med 2012; 18: 159-65.
320. [320] Jiang M, Wang J, Fu J, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets. Nat Med 2012;18: 153-9.
321. [321] Domnez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci 2012; 32: 124-32.
322. [322] Domnez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010; 142: 320-32.
323. [323] Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
324. [324] Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
325. [325] Feige JN, Lagouge M, Cantó C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2006; 8: 347-58.
326. [326] Rasbach KA, Schnellmann RG. Isoflavones promote mitochondrial biogenesis. J Pharmacol Exp Ther 2008; 325: 536-43.
327. [327] Funk JA, Odejinmi S, Schnellmann RG. SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J Pharm Exp Ther 2010; 333: 593-601.
328. [328] Feige JN, Lagouge M, Cantó C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008; 8: 347-58.
329. [329] Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285: 8340-51.
330. [330] Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005; 280: 17038-45.
331. [331] Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104: 7217-22.
332. [332] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
333. [333] Um JH, Park SJ, Kang H, et al. AMP-activated protein kinasedeficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-63.
334. [334] Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 1999; 25: 87-97.
335. [335] Cantó C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD+? Pharm. Rev 2012; 64: 166-87.
336. [336] Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006; 127: 1109-22.
337. [337] Menzies KJ, Singh K, Saleem A, Hood DA. Sirtuin 1-mediated effects of exercise and resveratrol on mitochondrial biogenesis. J. Biol. Chem 2013; 288: 6968-79.
338. [338] Ehses S, Raschke I, Mancuso G, et al. Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1. J Cell Biol 2009; 187: 1023-36.
339. [339] Head B, Griparic L, Amiri M, Gandre-Babbe S, van der Bliek AM. Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. J Cell Biol 2009; 187: 959-66.
340. [340] Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat Cell Biol 2011; 13: 589-98.
341. [341] Lovas JR, Wang X. The meaning of mitochondrial movement to a neuron’s life. Biochem Biophys Acta 2013; 1833: 184-94.
342. [342] Stowers RS, Megeath LJ, Gorska-Andrzejak J, Meinertzhagen IA, Schwarz TL. Axonal transport of mitochondria to synapses depends on Milton, a novel Drosophila protein. Neuron 2002; 36: 1063-77.